{"id":"NCT02044380","sponsor":"Boehringer Ingelheim","briefTitle":"Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations","officialTitle":"An Open Label Trial of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2016-02","completion":"2016-02","firstPosted":"2014-01-24","resultsPosted":"2017-03-31","lastUpdate":"2017-03-31"},"enrollment":14,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Afatinib","otherNames":[]}],"arms":[{"label":"Afatinib","type":"EXPERIMENTAL"}],"summary":"The main aim of this study is to evaluate the safety and tolerability of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s) and have never been treated with an EGFR-Tyrosine Kinase Inhibitor (TKI)","primaryOutcome":{"measure":"Safety Assesment","timeFrame":"From first administration of treatment until 28 days after last drug administration, up to 80 weeks.","effectByArm":[{"arm":"Afatinib 40 mg","deltaMin":92.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":14},"commonTop":["Diarrhoea","Nausea","Decreased appetite","Rash","Dysgeusia"]}}